BioWa is providing Agensys with access to its Potelligent Technology platform for the purpose of identifying antibodies with enhanced antibody-dependent cellular cytotoxicity (ADCC). Under the terms of the license agreement Agensys gains nonexclusive rights to conduct research using Potelligent for an undisclosed number of targets. In return BioWa will receive annual research license fees.
The Potelligent Technology has harnessed the ability to create 100% fucose-free mAbs, thereby enhancing ADCC, the critical factor in antitumor activity, according to BioWa. The amount of fucose in the carbohydrate structure of an antibody is reduced by using a proprietary fucosyltransferase-knockout CHO cell line for production, which improves potency and efficacy of antibody therapeutics.
"Agensys’ world-class R&D organization and breath of targets in solid tumors will greatly extend the benefits of the Potelligent Technology,” says Masamichi Koike, Ph.D., BioWa's president and CEO.